These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 31272080

  • 21. Ophiopogonin D' inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling.
    Xu T, Zhang W, Zhang Y, Song F, Huang P.
    J Cell Mol Med; 2024 Aug; 28(16):e70014. PubMed ID: 39153211
    [Abstract] [Full Text] [Related]

  • 22. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI, Kim DK, Seo EJ, Choi EJ, Kwon YW, Jang IH, Lee JC, Kim HY, Shong M, Kim JH, Kim SJ.
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [Abstract] [Full Text] [Related]

  • 23. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
    Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Alì G, Fontanini G, Basolo F, Francia G, Bocci G.
    Cancer Lett; 2017 Dec 28; 411():35-43. PubMed ID: 28964784
    [Abstract] [Full Text] [Related]

  • 24. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.
    Clin Cancer Res; 2016 Dec 15; 22(24):6192-6203. PubMed ID: 27307592
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 11; 39(5):2225-2234. PubMed ID: 29517103
    [Abstract] [Full Text] [Related]

  • 31. Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells.
    Li YT, Tian XT, Wu ML, Zheng X, Kong QY, Cheng XX, Zhu GW, Liu J, Li H.
    Int J Mol Sci; 2018 Mar 29; 19(4):. PubMed ID: 29596381
    [Abstract] [Full Text] [Related]

  • 32. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
    Wong K, Di Cristofano F, Ranieri M, De Martino D, Di Cristofano A.
    Endocr Relat Cancer; 2019 Apr 01; 26(4):425-436. PubMed ID: 30699064
    [Abstract] [Full Text] [Related]

  • 33. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    Endocrine; 2016 Feb 01; 51(2):274-82. PubMed ID: 26219406
    [Abstract] [Full Text] [Related]

  • 34. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C, Zhang R, Tan J, Meng Z, Zhang Y, Li N, Wang H, Chang J, Wang R.
    Oncol Rep; 2020 May 01; 43(5):1491-1502. PubMed ID: 32323855
    [Abstract] [Full Text] [Related]

  • 35. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
    Liu D, Xing J, Trink B, Xing M.
    Int J Cancer; 2010 Dec 15; 127(12):2965-73. PubMed ID: 21351275
    [Abstract] [Full Text] [Related]

  • 36. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W, Chen Y, Gong Y, Dong T, Zhang B, Gao W.
    Oncol Rep; 2016 Dec 15; 36(6):3387-3396. PubMed ID: 27779717
    [Abstract] [Full Text] [Related]

  • 37. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
    Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Theurer S, Hager T, Herold T, Kalbourtzis S, Bankfalvi A, Schmid KW, Führer D, Aigner C, Hegedűs B.
    Pathol Oncol Res; 2020 Oct 15; 26(4):2523-2535. PubMed ID: 32591993
    [Abstract] [Full Text] [Related]

  • 38. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2004 Dec 15; 10(24):8594-602. PubMed ID: 15623643
    [Abstract] [Full Text] [Related]

  • 39. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V, Baik C, Kirkwood JM.
    Trends Cancer; 2020 Sep 15; 6(9):797-810. PubMed ID: 32540454
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
    Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.
    J Mol Med (Berl); 2012 Oct 15; 90(10):1133-44. PubMed ID: 22399013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.